The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis
Abstract
Pulmonary fibrosis is a progressive life-threatening disease for which no effective therapy exists. Myofibroblasts are one of the key effector cells in pulmonary fibrosis and are the primary source of extracellular matrix production. Drugs that inhibit the differentiation of fibroblasts to myofibroblasts have potential as antifibrotic therapies. Peroxisome proliferator-activated receptor (PPAR)-γ is a transcription factor that upon ligation with PPARγ agonists activates target genes containing PPAR response elements. PPARγ agonists have anti-inflammatory activities and may have potential as antifibrotic agents. In this study, we examined the abilities of PPARγ agonists to block two of the most important profibrotic activities of TGF-β on pulmonary fibroblasts: myofibroblast differentiation and production of excess collagen. Both natural (15d-PGJ 2) and synthetic (ciglitazone and rosiglitazone) PPARγ agonists inhibited TGF-β-driven myofibroblast differentiation, as determined by α-smooth muscle actin-specific immunocytochemistry and Western blot analysis. PPARγ agonists also potently attenuated TGF-β-driven type I collagen protein production. A dominant-negative PPARγ partially reversed the inhibition of myofibroblast differentiation by 15d-PGJ 2 and rosiglitazone, but the irreversible PPARγ antagonist GW-9662 did not, suggesting that the antifibrotic effects of the PPARγ agonists are mediated through both PPARγ-dependent and independent mechanisms. Thus PPARγ agonists have novel and potent antifibrotic effects in human lung fibroblasts and may have potential for therapy of fibrotic diseases in the lung and other tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, N. S. A., Di Paola, R., Ialenti, A., Genovese, T., Chatterjee, P. K., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.056 · Cited by 214
RetractedMosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“This complex recognizes PPAR response elements (PPRE) in promoters on target genes resulting in the regulation of gene transcription (3, 5, 36).”
BackgroundRegulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Self-citationSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Self-citationTranscriptional Activators of TGF-β Responses: Smads
Derynck, R., Zhang, Y., & Feng, X.-H. (1998) · Cell · doi:10.1016/s0092-8674(00)81696-7 · Cited by 1,029
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 3×
“PPAR has anti-inflammatory activities, including the repression of the NF- B and activator protein (AP)-1 pathways (5, 6, 10).”
BackgroundThe Myofibroblast in Pulmonary Fibrosis*
Phan, S. H. (2002) · Chest · doi:10.1378/chest.122.6_suppl.286s · Cited by 521
The Role of Transforming Growth Factor β in Lung Development and Disease
Bartram, U., & Speer, C. P. (2004) · Chest · doi:10.1378/chest.125.2.754 · Cited by 495
Vaughan, M. B., Howard, E. W., & Tomasek, J. J. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4869 · Cited by 476
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway
Straus, D. S. (2000) · Medical Entomology and Zoology · Cited by 371
Inhibition of Myofibroblast Apoptosis by Transforming Growth Factor β 1
Zhang, H.-Y., & Phan, S. H. (1999) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.21.6.3720 · Cited by 353
Fibrosis of the Lung and Other Tissues: New Concepts in Pathogenesis and Treatment
Sime, P. J., & O'Reilly, K. M. A. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5008 · Cited by 330
Self-citationJordana, M., Schulman, J., McSharry, C., Irving, L. B., Newhouse, M. T., Jordana, G., & Gauldie, J. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/137.3.579 · Cited by 233
Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis
White, E. S., Lazar, M. H., & Thannickal, V. J. (2003) · The Journal of Pathology · doi:10.1002/path.1446 · Cited by 190
Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin
KOLB, M., MARGETTS, P. J., GALT, T., SIME, P. J., XING, Z., SCHMIDT, M., & GAULDIE, J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.3.2006084 · Cited by 189
Self-citationHata, K., Nishimura, R., Ikeda, F., Yamashita, K., Matsubara, T., Nokubi, T., & Yoneda, T. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-06-0356 · Cited by 187
Fu, M., Zhang, J., Zhu, X., Myles, D. E., Willson, T. M., Liu, X., & Chen, Y. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105490200 · Cited by 170
Kolb, M., Bonniaud, P., Galt, T., Sime, P. J., Kelly, M. M., Margetts, P. J., & Gauldie, J. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.27.2.4674 · Cited by 168
Self-citationBishop‐Bailey, D., & Wray, J. A. (2003) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(03)00003-0 · Cited by 151
Guo, B., Koya, D., Isono, M., Sugimoto, T., Kashiwagi, A., & Haneda, M. (2004) · Diabetes · doi:10.2337/diabetes.53.1.200 · Cited by 123
Chinetti, G., Fruchart, J., & Staels, B. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802499 · Cited by 111
Fu, M., Zhang, J., Lin, Y., Zhu, X., Zhao, L., Ahmad, M., Ehrengruber, M. U., & Chen, Y. E. (2003) · Biochemical Journal · doi:10.1042/bj20021503 · Cited by 85
Yu, C., Chen, L., Luo, H., Chen, J., Cheng, F., Gui, C., Zhang, R., Shen, J., Chen, K., Jiang, H., et al. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03937.x · Cited by 67
Park, Y., Freedman, B. D., Lee, E. J., Park, S., & Jameson, J. L. (2003) · Diabetologia · doi:10.1007/s00125-003-1037-4 · Cited by 44
Willey, J. J., Stripp, B. R., Baggs, R. B., & Gasiewicz, T. A. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8444 · Cited by 43
Mix, K. S., Coon, C. I., Rosen, E. D., Suh, N., Sporn, M. B., & Brinckerhoff, C. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.2.309 · Cited by 34
Cited by
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Metadata
- Authors
- Burgess, H. A., Daugherty, L. E., Thatcher, T. H., Lakatos, H. F., Ray, D. M., Redonnet, M., Phipps, R. P., & Sime, P. J.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2005-06
- Volume
- 288
- Issue
- 6
- Pages
- L1146-L1153
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2107356121
- Cited by
- 317
- References
- 38
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.